ERBB2 and breast carcinoma: Collectively, we have proposed a multifunctional DNA hydrogel for synergistic therapy of HER2-positive breast cancer with targeted codelivery therapeutic nucleic acid (HER2 aptamer) and chemodrugs (DOX).